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Abstract 
Treatments for pancreatic cancer can have debilitating side effects including fatigue, weight 
loss, and cardiac toxicity, resulting in functional loss and psychological distress. Exercise has 
been proposed as a therapy to counteract physical and psychological detriments. The case: A 
47-year-old male undergoing chemotherapy for stage 3 locally advanced pancreatic cancer. 
He was cycling during hospital chemotherapy infusions (6 fortnightly cycles of FOLFIRINOX: 5-
FU 2, 400 mg/m2, over 48 h: irinotecan 180 mg/m2, oxaliplatin 85 mg/m2, no 5-FU bolus) plus 
12 weeks of twice weekly aerobic and resistance exercise. Over 12 weeks, body composition 
was maintained, and physical function improved, with specific increases in muscular strength 
of up to 50% and aerobic capacity improving by 9%. Moreover, quality of life, fatigue, psycho-
logical distress, and sleep quality improved by 38, 113, 50, and 9%, respectively. Additionally, 
the participant experienced more severe side effects in week 6, when he did not cycle to a high 
intensity during hospital infusion and had less total weekly exercise. After cycle 6 (week 11), 
chemotherapy was halted, and a Whipple resection procedure was successfully performed. It 
can be concluded that regular aerobic and resistance exercise plus exercise during infusion can 
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attenuate expected decline in physical and mental health with pancreatic cancer treatment and 
may reduce treatment side effects and have favourable effects on prognosis. 
 © 2019 The Author(s) 
 Published by S. Karger AG, Basel 
Introduction 
The prognosis for pancreatic cancer is poor, with <5% of those with the condition surviv-
ing for 5 years and only 1% surviving 10 years after diagnosis [1]. For resectable pancreatic 
cancer (stage 1 and 2) survival rates are 7–25% at 5 years. Locally advanced (stage 3) and 
advanced cancer (stage 4) have an average survival of 6–11 months and 2–6 months, respec-
tively [1]. In addition to the poor prognosis, treatments for pancreatic cancer (primarily sur-
gery, chemotherapy, and radiotherapy) can have debilitating side effects, including fatigue 
which affects 92% of patients receiving chemotherapy [2]. Further complications with pan-
creatic cancer include weight loss, cardiac toxicity, digestive problems, diarrhoea, nausea, 
vomiting, increased infection risk, alopecia, and pain due to chemotherapy treatment [3]. Ad-
ditionally, psychological well-being decreases by 13% from pre- to post-treatment, with pan-
creatic cancer eliciting the highest rates of depression and anxiety compared to all other can-
cer types at 28.8 versus 18.5%, respectively [4]. Furthermore, disturbed sleep is also common 
in cancer survivors, with 43% of cancer patients having insomnia syndrome during chemo-
therapy treatment [5]. This translates to a decrease in quality of life (QOL) with FACT-Hep 
scores declining from pre- to post-treatment in pancreatic cancer patients [3]. Therefore, ther-
apies that improve treatment tolerance, reduce the loss of physical functioning, and improve 
psychological well-being are essential to improve QOL.  
Exercise has been proposed as such a therapy and has been investigated in other cancer 
types. As current, only one single case study exists which investigates the effects of exercise 
on physical and psychological well-being in pancreatic cancer [6]. This previous study inves-
tigated twice weekly aerobic and resistance training for 6 months in a 49-year-old male with 
stage 2b pancreatic cancer undergoing chemotherapy. The intervention was well-tolerated, 
with 73% attendance. At 12-weeks, exercise resulted in an improvement across all outcome 
measures, with an 8.2% increase in fat free mass, accompanied by a 31.6% increase in leg 
strength, and a decrease in time to complete 400 m walk, chair rise, stair climb, and 6 m walk 
(–5.9, –17.2, –9.9, and –23.5%, respectively). In addition to this, QOL improved by 40%, fatigue 
improved by 350%, sleep quality improved by 20%, and psychological distress improved by 
21%. The current study was undertaken to expand these findings by investigating exercise 
during chemotherapy infusion in addition to twice weekly aerobic and strength exercise in a 
case of stage 3 pancreatic cancer.  
Presenting Concerns 
A 47-year old white male with diagnosis of stage 3 locally advanced pancreatic cancer was 
recruited following a self-referral to MoveMore cancer exercise classes. He is married, a non-
smoker, and works in middle management. He initially presented with a 2–3 month history of 
epigastric pains, requiring hospital admission on one occasion. After symptoms failed to settle 
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with analgesia and omeprazole, he underwent further investigation with an endoscopic ultra-
sound and CT scan of his abdomen.  
Clinical Findings 
He had no medical history of note, and was taking omeprazole, tramadol and ibuprofen 
for symptom relief. There were no relevant family history or examination findings and he was 
ECOG performance status 0.  
Diagnostic Focus and Assessment 
Investigations confirmed the presence of a locally advanced pancreatic adenocarcinoma 
with invasion of the superior mesenteric vein, and proximity of the tumour to the hepatic ar-
tery and superior mesenteric artery. Baseline laboratory testing was unremarkable, with ex-
cellent liver and kidney function. As a consequence of the vascular involvement, he had an 
AJCC stage III pancreatic cancer which was considered inoperable.  
Therapeutic Focus  
The case received FOLFIRINOX (5-FU 2,400 mg/m2 over 48 h, irinotecan 180 mg/m2, ox-
aliplatin 85 mg/m2 – no 5-FU bolus) via peripherally inserted catheter administered over 6 
fortnightly cycles (12 weeks).  
During hospital chemotherapy infusions, the participant cycled for 40 min at 60% of heart 
rate maximum, using Polar Heart Rate Monitor. In addition, a 12-week exercise program, be-
ginning on week 2 of chemotherapy, was delivered as one-on-one sessions on two non- 
consecutive days/week, supervised by the researcher based on the following exercise pre-
scription: 
• 5-min warm-up and cool-down: light aerobic and flexibility exercises. 
• Resistance exercise: 8 exercises, performed for 3 sets of 12 repetitions at 60% of 1-
repetition maximum (1-RM), based on 12-RM baseline strength testing (leg press, leg 
extension, leg curl, calf raise, hip abduction, rear kick, back extension and leg raises). The 
participant did not perform upper body exercises as peripherally inserted central catheter 
was present.  
• Aerobic exercise: 15 min of continuous cycling on ergometer at 70% of maximum 
heart rate, based on maximal heart rate during baseline testing. Heart rate monitor worn 
throughout all sessions.  
Intensity and duration attenuated based on the participant’s health status. Therefore, ad-
herence and compliance were recorded throughout.  
Additional exercise out-with the program was advised, with the aim of accumulating 150-
min/week moderate intensity or 75-min vigorous intensity exercise in bouts of 10-min or 
more.  
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Aerobic Capacity: The participant cycled on an ergometer at 100 watts for 6 min. Heart 
rate measured every minute, using Polar heart rate monitor, and the steady state heart rate 
determined. This was extrapolated to corresponding VO2max estimation on Astrand Ryhming 
nomogram.  
Strength Testing (12-Repitition Maximum [RM]): The maximum load that can be per-
formed for 12-repetition was determined for leg press, leg extension, calf raise, leg curl, rear 
kick, hip abduction, and back extension.  
Flexibility: Seated toe-reach assessed flexibility of the hamstrings.  
Physical Function: Repeated chair rise (time taken to rise five times from a chair) evalu-
ated muscular power. Stair climb (time to ascend a flight of stairs) assessed ambulation. Usual 
pace, fast pace, and backwards 6-m walk evaluated ambulation and dynamic balance. Activi-
ties-Specific Balance Confidence scale evaluated falls self-efficacy.   
Body Composition: Bioelectrical impedance analysis assessed percentage body fat and 
lean mass.  
Physical Activity (PA) Levels: Apple watch assessed average weekly PA.  
Questionnaires: The Functional Assessment of Cancer Therapy–Hepatobiliary (FACT-
Hep) questionnaire evaluated pancreatic cancer-specific quality of life.  
Functional Assessment of Chronic Illness Therapy–Fatigue subscale assessed cancer-re-
lated fatigue.  
Pittsburgh Sleep Quality Index assessed sleep quality.  
The Brief Symptom Inventory-18 assessed psychological distress (depression, anxiety, 
somatization, and global distress severity).  
Semi-Structured Interview: Conducted at the end of the exercise program to elucidate if 
exercising during chemotherapy was truly meaningful. This consisted of 10 open-ended ques-
tions, delivered by the researcher, referring to the impact the intervention had on the partici-
pant’s quality of life, using a social validity approach. 
Follow-up and Outcomes 
The participant was assessed at baseline, 4, 8, and 12 weeks. Adherence to exercise during 
chemotherapy infusions was 100%, with compliance to exercise intensity reduced only dur-
ing week 6 (100 bpm vs. usual 124 bpm). This was due to use of an unfamiliar bicycle. Adher-
ence to the supervised exercise sessions was 94% (15/16 sessions). Reason for missed ses-
sion: on holiday. Average compliance to the supervised sessions varied from non-chemother-
apy to chemotherapy weeks at 100 and 68.67%, respectively. Performance intensity reduc-
tions during chemotherapy weeks were due to nausea. No adverse events from exercise. The 
participant experienced the following toxicities: grade 2 constipation, grade 2 nausea and 
vomiting, and grade 2 mucositis. These were managed successfully and did not result in treat-
ment delays or dose attenuations. 
With regards to exercise effects, there was a positive change in body composition from 
baseline to end of the training period, with a decrease in body fat percentage and increase in 
lean and total body mass (Table 1). In addition to altering body composition, exercise training 
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also induced increases in strength (Fig. 1). Furthermore, physical performance and aerobic 
capacity improved considerably with exercise (Fig. 2).  
With regards to psychological well-being, there were considerable improvements in qual-
ity of life, fatigue, and psychological distress, with sleep quality also showing a slight increase 
with exercise (Fig. 3). In addition to these results, qualitative feedback was obtained from the 
patient and is outlined in Table 2.  
After 6 weeks of chemotherapy (3 cycles), CT scan revealed partial tumour response, with 
further partial response on 12-week scan (after cycle 6), including improvement in previously 
noted vascular involvement of his locally advanced pancreatic cancer. Given the improvement, 
a successful Whipple’s pancreatico-duodenectomy was performed without requirement for a 
vascular reconstruction in September (final pathology: T2 N1 R1). The participant recovered 
well post-operatively and completed a further 6 cycles post-operative modified FOLFIRINOX 
(with reduced dose of irinotecan to 150 mg/m2 as per the adjuvant PRODIGE-24 trial protocol 
[7]). Cycle 12 was delivered with a further 20% dose reduction of 5-FU, oxaliplatin and iri-
notecan due to grade 2 diarrhoea with cycle 11. He is now recovering well from his chemo-
therapy. His Ca19–9 tumour marker remains within normal range and he is planning his re-
turn to work. 
Discussion 
Exercise was safe during chemotherapy for stage 3 pancreatic cancer, with appropriate 
attenuation of program when feeling nauseas. Twelve weeks of exercise increased lean muscle 
mass by 4.4%, translating into increased strength of up to 50% from baseline to week 12. 
These are significant findings as cancer cachexia affects 83% of those with pancreatic cancer, 
responsible for ~80% of advanced pancreatic cancer mortality [8]. Aerobic capacity also in-
creased with training, similar to the previous case study in pancreatic cancer [6]. Improve-
ments in both cardiovascular function and strength are translated into improved physical 
function, important for maintaining independence of activities of daily living. Usually, chemo-
therapy results in fatigue sub-scores on FACT-Hep reducing from 1.30 at baseline to 0.80 at 4 
and 8 weeks in those with pancreatic cancer [3] due to cachexia, loss of physical function, and 
psychological distress due to treatment toxicity and tumour-specific cytokine release [9]. This 
case had large and progressive improvements in fatigue. This is an important finding as can-
cer-related fatigue upsets daily routines of 88% of sufferers, with 75% of those changing em-
ployment status [10]. Hence, exercise may be a therapy which can aid maintenance of normal 
lifestyle by counteracting the usual expected side effects of cachexia and declines in physical 
functioning. 
It is important to discuss the finding from week 6 whereby the participant reported feel-
ing physically and mentally poorly after exercising at a lesser intensity during chemotherapy 
infusion. It may be speculated that, due to increased side effects from his chemotherapy, the 
case was too fatigued to exercise to the same intensity. It could be equally speculated that 
exercise during infusion may have to be at a high intensity to reduce treatment-related side 
effects. The mechanism suggested for this is redirection of blood flow to muscle tissue during 
exercise, reducing the splanchnic organ contact with the chemotherapy treatment [11]. This 
enhances treatment tolerance and is likely to contribute to treatments being on time. Addi-
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tionally, exercise may increase treatment efficacy by increasing tumour blood flow and sub-
sequent chemotherapy delivery. The tumour vasculature does not respond to vasoconstric-
tive signals during exercise, allowing increased blood flow to the tumour [11], with a 140% 
increase in tumour perfusion in breast cancer mice, translating to reduced tumour hypoxia 
and decreased tumour development, compared with usual care [12]. This may be because hy-
poxia causes chemoresistance as low vascularization limits the delivery of chemotherapy to 
the tumor [13]. Therefore, decreased tumour development is postulated to be due to an exer-
cise-induced increase in efficacy of chemotherapy by increasing tumour blood supply.  
Additionally, sleep quality also improved by the end of the intervention; and psychologi-
cal distress moved from ‘severe mental disorder’ to ‘mild mental disorder’ from baseline to 4 
weeks, and ‘likely to be well’ by week 8. Overall, well-being improved, with increased strength, 
fitness, physical functioning, and improved ability to psychologically cope with treatment, 
translating to improved QOL. The inclusion of qualitative data adds social validity to the nu-
merical findings, and from Table 2 it can be determined that exercise is truly meaningful to 
the participant’s life. Additionally, exercise during infusion gives the participant ‘something to 
look forward to’ and a perception of control (Table 2). This is consistent with a previous study 
of exercise during infusion whereby it was found that cycling during infusion was “4% more 
comfortable, 15% less difficult, and 69% less boring” than usual care [14]. Hence, reduced side 
effects of treatment by cycling during infusion may be both psychological and physiological. 
However, it is important to note that he was also seeing a psychologist regularly throughout 
his chemotherapy, which will have undoubtedly contributed to improved psychological well-
being. 
Unfortunately, cause-effect cannot be determined. The lack of reported treatment side ef-
fects may be due to high levels of exercise; or it may be the limited side effects which allows 
compliance to the intervention. Achieving high levels of exercise may not be possible for those 
experiencing severe side effects. Moreover, the case is relatively young, compared to the av-
erage age of 71 years for diagnosis of pancreatic cancer [15] and hence, results may not be 
applicable to all pancreatic cancer patients.  
Conclusions 
Exercise is safe and effective during treatment for locally advanced pancreatic cancer. 
This case study has confirmed findings that exercise attenuates expected declines in pancre-
atic cancer patients, adding to literature that exercising during infusions is also safe and may 
decrease side effects and aid efficacy of chemotherapy treatment. Findings have clinical im-
plications, and it is recommended that a supervised exercise program and exercise during 
chemotherapy infusions should be included as an adjunct to usual treatment for pancreatic 
cancer. In the future, clinical trials of supervised exercise programs are required to expand 
these findings. 
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Fig. 1. Muscular strength endurance of leg press, extension and curl, calf raise, rear kick, hip abduction 
and back extension, measured by 12-repetition maximum (kg), at 0, 4, 8, and 12 weeks of the exercise 




Fig. 2. Physical performance and fitness, measured by a submaximal Astrand fitness test, stair climb time, 
6 m walk test and 30 s chair rise test, reported as the improvement (%) from baseline to week 4, 8, and 
12 of the exercise intervention. Measurements were taken on 3 consecutive attempts and the average 
score reported (except from Astrand test, which was performed once, and the result reported).  
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Fig. 3. Psychological well-being, measured by self-reported questionnaires for quality of life, fatigue, psy-
chological distress and sleep quality, reported as the improvement (%) from baseline to week 4, 8, and 





Table 1. Body composition at baseline and week 12 
   
   
Measurement Baseline Week 12 
   
   
Body mass, kg 80.8 82.7 
Body fat, % 17.7 13.3 
Lean mass, % 82.3 86.7 
   




Table 2. Semi-structured interview results 
   
   
Question   Key Words  
   
   
How has exercise helped you cope with  
treatment? 
 Feel different to other cancer patients  
In control 
Proud 
      What are your main motivators for doing  
this exercise programme? 
 Fear of death 
      How would you describe your experience  
of this programme? 
 Hopeful 
Purposeful 
Team effort (social) 
Don’t feel isolated 
      Have any side effects of treatment been a  
problem for exercising? 
 Nausea a big problem in first week 
Frustrating 
      What do you think are the benefits of  
cycling during infusion? 
 Something to look forward to 
Not easy but makes a big difference 
Helps to aid recovery from treatment: Felt  
awful for a full week when bike was stolen but  
all other times recovered after a few days 
   
   
 
 
 
